Ovid Therapeutics (OVID) Equity Ratio (2016 - 2026)

Ovid Therapeutics has reported Equity Ratio for 11 years, with the latest figure at 0.88 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 21.05% year-over-year to 0.88; the trailing twelve-month figure through Mar 2026 stood at 0.88 (up 21.05% YoY), and the FY2025 full-year result was 0.87, up 16.94% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.88, up from 0.87 in the prior quarter.
• The five-year high for Equity Ratio was 0.88 in Q1 2026, with the low at 0.59 in Q1 2024.
• Historically, Equity Ratio has averaged 0.78 across 5 years, with a median of 0.81 in 2023.
• Annual changes were most pronounced in 2024 — Equity Ratio declined 29.5% — and 2025, when it gained 22.05%.
• Ovid Therapeutics' Equity Ratio stood at 0.85 in 2022, then declined by 28.44% to 0.61 in 2023, then increased by 21.43% to 0.74 in 2024, then advanced by 16.94% to 0.87 in 2025, then gained by 1.51% to 0.88 in 2026.
• The last three Equity Ratio figures came in at 0.88 (Q1 2026), 0.87 (Q4 2025), and 0.7 (Q3 2025), per Business Quant data.